Project Grant R01AG084723
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$716K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $125,896 to The Washington University in St. Louis to conduct research aimed at characterizing the genetic and molecular pathways underlying Alzheimer's disease (AD) risk and resilience. The key objectives are to: 1) dissect the role of non-coding genetic variants in AD risk through multi-omic profiling of healthy and AD brain tissue; 2) identify protective mechanisms in cognitively...
This $2,365,042 Project Grant award from the National Institute on Aging's Aging Research Program (CFDA 93.866) supports research to better understand the biological underpinnings of Alzheimer's disease and related dementias (ADRD). The primary objectives are to leverage cross-national data from the U.S. and India to evaluate associations between neurodegenerative biomarkers, cognitive outcomes, and socioeconomic factors. Key project activities include developing harmonized measures for...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $455,274 to The Johns Hopkins University to develop and apply statistical methods for analyzing the risk of Alzheimer's disease and biomarker measurements. The key objectives are to: 1) Handle bias from prevalent Alzheimer's cases in case-control studies, 2) Develop regression methods to analyze age at biomarker positivity and time to onset of clinical symptoms, and 3) Develop statistical...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to investigate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The $459,250 award to The General Hospital Corporation (Massachusetts General Hospital) aims to: 1) optimize fingerstick collection methods and validate assays for measuring key AD biomarkers (pTau217, GFAP, NFL) in capillary DBS samples; 2) establish if DBS biomarker...
This $155,000 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research at Wake Forest University Health Sciences (WFUHS) to identify potential microRNA (miRNA) biomarkers for early detection and progression of Alzheimer's disease (AD). The key objectives are to: Discover circulating miRNA biomarkers that can distinguish between individuals at different stages of AD, including those with mild cognitive impairment. This could enable earlier...
This $1,205,827 Project Grant, awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), will examine the role of environmental exposures as a risk factor for Alzheimer's disease (AD) among non-Hispanic Whites, African Americans, and Mexican Americans. The project will utilize blood samples from 3,000 participants in the ongoing Health & Aging Brain Study - Health Disparities Study to investigate the "exposome" and its impact on AD development within these...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a 5-year, $1,550,462 study to investigate the impact of Alzheimer's disease (AD) risk genes on brain function in HIV-positive older Black/African American adults. The multidisciplinary study will enroll 120 HIV-positive participants (60 with and 60 without the APOE E4 gene variant) and 80 demographically matched controls to assess cognitive function, brain imaging, and biomarkers related to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,281,385 to the University of California, San Diego (UCSD) to leverage 30 years of Alzheimer's disease clinical trials data. The goal is to examine the role of specific phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions. The study will analyze data from 14,602 participants across multiple clinical trials, looking at...
This $885,006 project grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a smartphone-based point-of-care diagnostic system to detect Alzheimer's disease (AD) biomarkers, including amyloid-beta, phosphorylated tau, and neurofilament light chain, in blood plasma. The primary recipient, Brigham & Women's Hospital Inc., will leverage microfluidics, nanotechnology, optical sensing, and deep learning to create an affordable, user-friendly test that can...
This $794,981 Project Grant award from the National Institutes of Health's National Institute on Aging (CFDA 93.866 - Aging Research) will fund research by the University of California, San Diego to investigate blood-brain barrier dysfunction and brain microstructural changes as biomarkers for predicting and monitoring amyloid-related imaging abnormalities (ARIA) and treatment outcomes with anti-amyloid immunotherapies for Alzheimer's disease. The 5-year project will integrate advanced MRI...